Skip to main content

Treatment Clinical Trials for Prostate Cancer

Review the prostate cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 251-275 of 315

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients with PSCA+ Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Status: Active
Location: 2 locations
An Extended Course of Sipuleucel-T Immunotherapy for Treating Patients with Metastatic Castration-resistant Prostate Cancer, EXCITE Trial
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Relugolix and Enzalutamide for the Treatment of High-Risk Locally Advanced Prostate Cancer
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
REGN5678 and Cemiplimab for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
177^Lu-PSMA-617 in Combination with Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Stereotactic Body Radiation Therapy for the Treatment of Patients with Advanced Prostate Cancer, PRORAD-5 Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cabozantinib in Combination with Lutetium-177 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CaboLu Study
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Gamitrinib for the Treatment of Advanced or Refractory Solid Tumors or Lymphoma
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
177Lu-PSMA-617 with Liver Directed Therapy for the Treatment of Castration Resistant Prostate Cancer with Liver Metastasis
Status: Active
Location: University of California San Francisco, San Francisco, California
pTVG-HP DNA Vaccine + Nivolumab + Targeted Radiation Therapy to Resistant Lesions for the Treatment of Biochemically Recurrent, Oligometastatic Prostate Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Status: Active
Location: 5 locations
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Status: Active
Location: 2 locations
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Differences in Immunological Effects of Vitamin D Replacement among African American Prostate Cancer Patients with Localized versus Metastatic Disease
Status: Active
Location: 2 locations